Client: Fortune 500 Life Sciences Manufacturer.
Objective: A major life sciences manufacturer wanted to reduce high void rates and non-adherence among new patients using a GLP-1 medication. The traditional single-channel approach proved ineffective, as it involved broad, untargeted messaging that often failed to convert patients into consistent users. The goal was to implement a more effective strategy that could better target potential adherents and eliminate messaging waste...